June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Multidisciplinary pathway for orbital lymphoma
Author Affiliations & Notes
  • John Bladen
    Orbital, Kings College Hospital NHS Foundation Trust, United Kingdom
  • Ziyaad Sultan
    Orbital, Kings College Hospital NHS Foundation Trust, United Kingdom
  • Jessica Brady
    Clinical Oncology, St Thomas' Hospital, London, London, United Kingdom
  • George Mikhaeel
    Clinical Oncology, St Thomas' Hospital, London, London, United Kingdom
  • Jon Salisbury
    Histopathology, Kings College Hospital NHS Trust, United Kingdom
  • Steve Connor
    Neuroimaging, Kings College NHS Foundation Trust, United Kingdom
  • Stella Bowcock
    Haematology Chartwell Unit, Kings College NHS Foundation Trust, United Kingdom
  • Footnotes
    Commercial Relationships   John Bladen None; Ziyaad Sultan None; Jessica Brady None; George Mikhaeel None; Jon Salisbury None; Steve Connor None; Stella Bowcock None
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 3153 – A0048. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      John Bladen, Ziyaad Sultan, Jessica Brady, George Mikhaeel, Jon Salisbury, Steve Connor, Stella Bowcock; Multidisciplinary pathway for orbital lymphoma. Invest. Ophthalmol. Vis. Sci. 2022;63(7):3153 – A0048.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Evaluating a new, comprehensive orbital lymphoma service. A prospective case series was carried out to evaluate the pathway and to identify common themes in orbital lymphoma

Methods : 20 patients (mean age 67 SD14.4; M:F 1:1). presented to ophthalmology over 2 years, were managed on a pathway involving MDT care across ophthalmology, haematology, pathology, oncology and radiotherapy. Baseline investigations included MRI orbits, half-body PET-CT scan, FBC, U&E, Calcium, LDH LFT, ESR, HIV, Hepatitis B&C, open orbital biopsy and bone marrow biopsy. Patients were recorded under AJCC v8 TNM for ocular adnexal lymphoma and Ann-Arbor (AA) staging systems. All patients were discussed at the weekly haematology-oncology MDT on confirmation of histological diagnosis. Those undergoing radiotherapy have an imaging response assessment at 3 months with subsequent long-term follow-up under joint haematology-ophthalmic care

Results : The pathway was completed by 16 cases, 1 case was palliated prior to biopsy, 1 had a diagnostic pancreatic biopsy, 2 followed up elsewhere. Commonest presentation was ptosis (5), palpable mass (4), proptosis (3), conjunctival lesion (2) and epiphora (2). Two had contiguous, bilateral orbital disease. Histology: 11 EMZL, 4 DLBCL, 1 SLL. Bone marrow involvement in 1 EMZL and 1 DLBCL. Doxycycline had no effect on 2 conjunctival lesions. Mean time from biopsy to treatment (radiotherapy or chemotherapy) 61 days. Radiotherapy was given to 11 (4-30Gy). DBCL received 3 cycles of R-CHOP. 15 had radiologic remission with 1 contracted lesion considered remission

Conclusions : A multi-disciplinary approach is essential in managing orbital lymphoma. Doxyxycline had no effect and higher doses of radiotherapy was required in some EMZL. Bone marrow biopsy is essential for staging. Having expertise within each area provides a comprehensive patient experience, however coordination between multiple sites and locations can pose difficulties in running a smooth and timely pathway

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×